Preclinical evaluation of the cardiac toxicity of HMR-1826, a novel prodrug of doxorubicin

British Journal of Cancer

Volumn 81, Issue 1, 1999, Pages 24-27

  Platel, D ^a   Bonoron Adele S ^b   Dix, R K ^c   Robert, J ^a  

^a INSTITUT BERGONIÉ   (France)

^b INSERM   (France)

^c Hoescht Marion Roussell   (United States)

Author keywords

Anthracyclines; Cardiotoxicity; Prodrug therapy

Indexed keywords

ANTHRACYCLINE; DOXORUBICIN; GLUCURONIC ACID; LIPOSOME; N (4 BETA GLUCURONYL 3 NITROBENZYLOXYCARBONYL)DOXORUBICIN; PRODRUG; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CONTROLLED STUDY; DIARRHEA; DRUG CAPSULE; DRUG TARGETING; DRUG TOLERANCE; EPISTAXIS; HEART LEFT VENTRICLE CONTRACTILITY; HEART LEFT VENTRICLE PRESSURE; HEART MUSCLE RELAXATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; WEIGHT REDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; BODY WEIGHT; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG EVALUATION, PRECLINICAL; GLUCURONATES; HEART DISEASES; MALE; MYOCARDIAL CONTRACTION; MYOCARDIUM; PRODRUGS; RATS; RATS, SPRAGUE-DAWLEY; VENTRICULAR DYSFUNCTION, LEFT;

EID: 0032833334     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690646     Document Type: Article

References (11)

1. Baurain R, Deprez-De Campaneere D and Trouet A (1979) Rapid determination of doxorubicin and its fluorescent metabolites by high pressure liquid chromatography. Anal Biochem 94: 112-116
2. Bosslet K, Straub R, Blumrich M, Czech J, Gerken M, Sperker B, Kroemer HK, Gesson JP, Koch M and Monneret C (1998) Elucidation of the mechanism enabling tumor selective prodrug monotherapy. Cancer Res 58: 1195-1201
3. Connors TA and Whisson ME (1966) Cure of mice bearing advanced plasma cell tumours with aniline mustard: the relationship between glucuronidase activity and tumour sensitivity. Nuture 210: 866-867
4. Duncan R, Coatsworth JK and Burtles S (1998) Preclinical toxicology of a novel polymeric antitumour agent: HPMA copolymer-doxorubicin (PKI). Human Exp Toxicol 17: 93-104
5. Morent JC, Gaudel G, Mitaku S, Monneret C, Gesson JP, Jacquesy JC, Mondon J, Martine C, Renoux B, Adrianomenjanahary S, Michel S, Koch M, Tillequin F, Gerken M, Czech J, Straub R and Bosslet K (1998) Prodrugs of anthracyclines for use in antibody-directed enzyme prodrug therapy. J Med Chem 41: 3572-3581
6. Lorell BH, Wexler LF, Momomura S, Weinberg F. and Apstein CS (1986) The influence of pressure overload left ventricular hypertrophy on diastolic properties during hypoxia in isovolumically contracting rat hearts. Cirr Res 58: 653-663
7. Mouridsen HT (1992) Systemic therapy for advanced breast cancer, Drugs 44: 17-28
8. Muerdter TE, Sperker B, Kivislö KT, McClellan M, Fritz P, Friedel G, Linder A, Bosslet K, Toomes H, Dierkesmann R and Kroemer HK (1997) Enhanced uptake of doxorubicin into bronchial carcinoma: β-glucuronidase mediates release of doxorubicin from a glucuronide prodrug. Cancer Res 57: 2440-2445
9. Pouna P, Bonoron-Adèle S, Gouverneur G, Tariosse L, Besse P and Robert J (1996) Development of the model of rat isolated perfused heart for the evaluation of anthracycline cardiotoxicity and its circumvention. Br J Pharmacol 117: 1593-1599
10. Von Hoff DD, Layard MW, Basa P, Davies HL, Von Hoff AL, Rozencweig M and Muggia FM (1979) Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91: 710-717
11. Working PK and Dayan AD (1996) Pharmacological-toxicological expert report: Caelyx™ (Stealth⊙ liposomal doxorubicin HCI). Human Exp Toxicol 15: 752-785